Clinical Trial Update: CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy in patients with relapsed or refractory multiple myeloma; currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy

Snippet

Sponsor: Caribou Biosciences, Inc. | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING